Acura Pharmaceuticals Announces NEXAFED Pseudoephedrine Tablets Disrupt Methamphetamine Production

Acura Pharmaceuticals, Inc. ACUR today announced independent laboratory tests demonstrated that NEXAFED, Acura's pseudoephedrine tablet product, disrupted the conversion of the pseudoephedrine in the product into methamphetamine. These most recent laboratory tests used the direct conversion or "one-pot" method. In previous testing, NEXAFED has also demonstrated the ability to block the extraction of the pseudoephedrine from the tablets, which is the first step in the two other common methods of producing the illicit drug methamphetamine. NEXAFED is a 30 mg pseudoephedrine hydrochloride tablet formulation utilizing Acura's IMPEDE Technology and intended to be used as a treatment for nasal congestion associated with colds and allergies. Acura expects to make NEXAFED available to pharmacies later this year.